ECTRIMS: New Biologic Drug Shows Promise in MS (CME/CE)

AMSTERDAM (MedPage Today) — Treatment with daclizumab cut annualized relapse rates in half among patients with early relapsing-remitting multiple sclerosis, according to the results of a placebo-controlled trial.

http://www.medpagetoday.com/MeetingCoverage/ECTRIMS/29187

Sent with MobileRSS for iPhone

Júlio Leonardo B. Pereira
http://lattes.cnpq.br/7687651239699170
http://www.neurocirurgiabr.orghttp://www.neurocancer.com



Categories: Uncategorized

Tags:

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: